Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
Business Wire•01/10/2026•08:34 ET
0
Key Highlights
- ➤13 abstracts accepted for ESMO Congress 2026 presentation by Tempus AI (TEM)
- ➤October 23–27 Madrid congress showcases oncology research across prostate, breast, NSCLC and other solid tumors
- ➤Tempus (TEM) will highlight Tempus Lens, Tempus One and foundation models at booths #1068 & #1069
Expert Statements
Ezra Cohen, Chief Medical Officer of Oncology at Tempus
“Across 13 abstracts at ESMO, researchers are using Tempus’ real-world multimodal data to identify clinically meaningful differences in cancer biology, treatment response and patient outcomes.”
Ezra Cohen, Chief Medical Officer of Oncology at Tempus
“By connecting molecular data with clinical histories and outcomes, these studies are generating insights that can inform biomarker development, patient stratification and clinical trial design, helping to advance precision oncology research.”
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid.
Get started
Create a free account to read the full story.